Hikma Adds Remsima SC To Celltrion MENA Collaboration
Subcutaneous Version Of Infliximab Joins Three Other Celltrion Biosimilars
Hikma has added Celltrion’s Remsima SC subcutaneous formulation of biosimilar infliximab to a marketing alliance in the MENA region that already includes three other Celltrion biosimilars.
You may also be interested in...
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.
Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.